Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Curvilinear versus phased array transducer: using the obstetric ultrasound for focused cardiac ultrasound in laboring patients - a randomized controlled assessment.

International journal of obstetric anesthesia·2025
Same author

Epicardial fat thickness correlates with P-wave duration, left atrial size and decreased left ventricular systolic function in morbid obesity.

Nutrition, metabolism, and cardiovascular diseases : NMCD·2017
Same author

Long-term effects of human amniotic membrane in a rat model of biliary fibrosis.

Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas·2017
Same author

[Not Available].

Arquivos brasileiros de cardiologia·2016
Same author

Subclinical left ventricular dysfunction in childhood-onset systemic lupus erythematosus: a two-dimensional speckle-tracking echocardiographic study.

Scandinavian journal of rheumatology·2015
Same author

Subclinical right ventricle systolic dysfunction in childhood-onset systemic lupus erythematosus: insights from two-dimensional speckle-tracking echocardiography.

Lupus·2014

Related Experiment Video

Updated: Jun 19, 2026

Parasite Induced Genetically Driven Autoimmune Chagas Heart Disease in the Chicken Model
09:23

Parasite Induced Genetically Driven Autoimmune Chagas Heart Disease in the Chicken Model

Published on: July 29, 2012

Chagas cardiomyopathy and captopril.

R R Roberti1, E E Martinez, J L Andrade

  • 1Division of Cardiology, Escola Paulista de Medicina, Sao Paulo, Brazil.

European Heart Journal
|July 1, 1992
PubMed
Summary

Captopril treatment significantly reduced heart rate and ventricular arrhythmias in Chagas disease patients with heart failure. This suggests captopril may decrease mortality in Chagas disease patients.

More Related Videos

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
10:08

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

Published on: February 17, 2018

In Vitro Drug Screening Against All Life Cycle Stages of Trypanosoma cruzi Using Parasites Expressing β-galactosidase
08:48

In Vitro Drug Screening Against All Life Cycle Stages of Trypanosoma cruzi Using Parasites Expressing β-galactosidase

Published on: November 5, 2021

Related Experiment Videos

Last Updated: Jun 19, 2026

Parasite Induced Genetically Driven Autoimmune Chagas Heart Disease in the Chicken Model
09:23

Parasite Induced Genetically Driven Autoimmune Chagas Heart Disease in the Chicken Model

Published on: July 29, 2012

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
10:08

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

Published on: February 17, 2018

In Vitro Drug Screening Against All Life Cycle Stages of Trypanosoma cruzi Using Parasites Expressing β-galactosidase
08:48

In Vitro Drug Screening Against All Life Cycle Stages of Trypanosoma cruzi Using Parasites Expressing β-galactosidase

Published on: November 5, 2021

Area of Science:

  • Cardiology
  • Infectious Diseases
  • Pharmacology

Background:

  • Chagas disease is a major cause of heart failure and sudden death in Latin America.
  • Approximately 40% of Chagas disease patients with heart failure experience sudden death.

Purpose of the Study:

  • To evaluate the effects of captopril on ventricular arrhythmias, neurohormones, and electrolytes in Chagas disease patients with advanced heart failure.
  • To assess the potential of captopril in reducing mortality associated with Chagas disease.

Main Methods:

  • A single-blind, cross-over trial involving 18 Chagas disease patients (NYHA Class IV heart failure) on stable digoxin and frusemide.
  • Patients received either captopril (up to 150 mg/day) or placebo for 6 weeks, followed by a 2-week washout and then crossed over.
  • Evaluations included 24-hour Holter monitoring, 2-D echocardiography, urinary catecholamines, plasma renin, and electrolytes.

Main Results:

  • Captopril treatment led to a significant reduction in heart rate and urinary catecholamine levels.
  • Enhanced plasma renin levels were observed in the captopril-treated group.
  • A significant reduction in ventricular couplets (a marker of arrhythmias) was noted with captopril.

Conclusions:

  • Captopril demonstrates beneficial effects on neurohormonal balance in Chagas disease patients with heart failure.
  • The reduction in heart rate and ventricular arrhythmias suggests captopril may decrease mortality in this patient population.
  • Further research is warranted to confirm the mortality-reducing potential of captopril in Chagas disease.